However, despite being a negative prognostic factor for ovarian cancer patients (227), CD44 widespread expression makes it a suitable target for nanoparticle-mediated therapy, as it can overcome drug resistance and improve drug delivery and accumulation in tumor tissue. This evidence concerns the gene CD44 and ovarian carcinoma.